Skip to content

Treatment of Oral Submucous Fibrosis with Xanthinol Nicotinate, Dexamethasone and Levamisole.

Comparative study of therapeutic efficacy of Xanthinol Nicotinate, Dexamethasone and Levamisole in treatment of Oral Submucous Fibrosis in Saurashtra region. - OSMF

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019008
Enrollment
90
Registered
2019-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K135- Oral submucous fibrosis

Interventions

Intervention1: 1- xanthinol nicotinate 2- levamisole 3- dexamethasone: Patients will be given 2 ml intralesional injection of Xantinol Nicotinate once a week along with oral antioxidant and phy

Sponsors

Dr Shaikh Saba Sultana
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed case of OSMF. Patients within age group of 20-40 years. Patients who were willing for follow up visits and to quit the habit of areca nut chewing.

Exclusion criteria

Exclusion criteria: Pregnant ladies and lactating mothers Patient allergic to study drugs or with positive drug history of anticoagulants. Previous history of OSMF treatment Systemic diseases e.g. diabetes mellitus, hypertension, aneamic stomatitis, radiation fibrosis , scleroderma, cardiac disorders.

Design outcomes

Primary

MeasureTime frame
interincisal mouth opening tongue protrusion burning sensationTimepoint: interincisal mouth opening tongue protrusion burning sensation will be assessed every week for 2 months

Secondary

MeasureTime frame
fibrous band status ulceration in oral cavityTimepoint: will be assessed every week for 2 months

Countries

India

Contacts

Public ContactDr Shaikh Saba Sultana

College of dental science and hospital

adaljachhaya@yahoo.in9725676269

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026